Cargando…

P23: RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS. A MULTICENTER RETROSPECTIVE ANALYSIS OF ELIGIBILITY CRITERIA FOR CAR-T CELL THERAPY.

Detalles Bibliográficos
Autores principales:	Fazio, F, Di Rocco, A, Za, T, Tomarchio, V, Rago, A, Piciocchi, A, Caravita di Toritto, T, Annibali, O, De Stefano, V, Foà, R, Martelli, M, Petrucci, MT
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Poster
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009814/ http://dx.doi.org/10.1097/01.HS9.0000829664.02846.2b

Ejemplares similares

P902: RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS. A MULTICENTER RETROSPECTIVE ANALYSIS OF ELIGIBILITY CRITERIA FOR CAR-T CELL THERAPY
por: Fazio, F., et al.
Publicado: (2022)

Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group
por: Fazio, Francesca, et al.
Publicado: (2022)

P25 EFFECT OF DARATUMUMAB ON STEM CELL YIELDS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: REPORT FROM THE MULTIPLE MYELOMA LAZIO GROUP
por: Fazio, F., et al.
Publicado: (2023)

Identifying the link between multiple myeloma and neurofibromatosis type I
por: Rago, Angela, et al.
Publicado: (2020)

P971: EFFECT OF DARATUMUMAB ON STEM CELL YIELDS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: REPORT FROM THE MULTIPLE MYELOMA LAZIO GROUP.
por: Fazio, Francesca, et al.
Publicado: (2023)

P62 USE OF ANTIVIRAL FOR PAUCISINTOMATIC COVID-19 INFECTION IN MULTIPLE MYELOMA PATIENTS UNDERGOING TREATMENT
por: Annibali, O., et al.
Publicado: (2023)

Immunotactoid glomerulopathy and chronic lymphocytic leukemia: The need for a multidisciplinary approach
por: Rago, Angela, et al.
Publicado: (2022)

P64 A CASE OF COVID-19 PNEUMONIA AFTER CAR T-CELL THERAPY IN A PATIENT AFFECTED BY RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Ielo, C., et al.
Publicado: (2023)

P04 MULTIPARAMETRIC FLOW CYTOMETRY REFINES RISK STRATIFICATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
por: Fazio, F., et al.
Publicado: (2023)

PB2024: PREVALENCE OF TYPE 1 GAUCHER DISEASE IN PATIENTS WITH MULTIPLE MYELOMA: FIRST INTERIM ANALYSIS OF A PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY
por: Offidani, M., et al.
Publicado: (2022)

Consensus for Flow Cytometry Clinical Report on Multiple Myeloma: A Multicenter Harmonization Process Merging Laboratory Experience and Clinical Needs
por: Cordone, Iole, et al.
Publicado: (2023)

Multiparametric Flow Cytometry in Newly Diagnosed Multiple Myeloma Patients: An Italian Monocentric Experience
por: Fazio, Francesca, et al.
Publicado: (2023)

The criteria of eligibility to the extracorporeal treatment
por: Zangrillo, A
Publicado: (2012)

Alkaline phosphatase (alp) levels in multiple myeloma and solid cancers with bone lesions: Is there any difference?
por: Annibali, O., et al.
Publicado: (2020)

P26: EXTRAMEDULLARY MULTIPLE MYELOMA: A MONOCENTRIC RETROSPECTIVE OBSERVATIONAL STUDY
por: Brescini, M, et al.
Publicado: (2022)

Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
por: Offidani, M, et al.
Publicado: (2013)

Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success
por: Inzoli, Elena, et al.
Publicado: (2022)

Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies
por: Bringhen, Sara, et al.
Publicado: (2019)

Epilepsy surgery: eligibility criteria and presurgical evaluation
por: Ryvlin, Philippe, et al.
Publicado: (2008)

Analysis of Eligibility Criteria Complexity in Clinical Trials
por: Ross, Jessica, et al.
Publicado: (2010)

Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials
por: van Eijk, Ruben P.A., et al.
Publicado: (2019)

The Treatment of Multiple Myeloma Patients Not Eligible for Asct
por: Richardson, Paul, et al.
Publicado: (2010)

Induction Treatment in Transplant-eligible Multiple Myeloma
por: Quinn, J., et al.
Publicado: (2021)

A review of research on eligibility criteria for clinical trials
por: Su, Qianmin, et al.
Publicado: (2023)

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
por: Su, Christopher T., et al.
Publicado: (2021)

Opportunities for Participation in Randomized Controlled Trials for Patients with Multiple Myeloma: Trial Access Depends on Restrictive Eligibility Criteria and Patient Expectations
por: Boquoi, Amelie, et al.
Publicado: (2022)

Discordance between clinical and immunological ART eligibility criteria for children in Malawi
por: O’Hare, Bernadette, et al.
Publicado: (2014)

The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma
por: Bobin, Arthur, et al.
Publicado: (2020)

Protective Isolation for Patients with Haematological Malignancies: A Pilot Study Investigating Patients’ Distress and Use of Time
por: Annibali, O., et al.
Publicado: (2017)

Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
por: Morè, Sonia, et al.
Publicado: (2020)

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
por: Jones, John R., et al.
Publicado: (2023)

The impact of eligibility criteria on enrollment in ICU sepsis clinical trials
por: Foster, D, et al.
Publicado: (1999)

Long-Term Care Eligibility Criteria for People with Alzheimer's Disease
por: Fox, Patrick, et al.
Publicado: (1999)

Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria
por: Franzen, Sanne, et al.
Publicado: (2021)

Anatomic Repair of Congenitally Corrected Transposition: Reappraisal of Eligibility Criteria
por: Weixler, Viktoria H. M., et al.
Publicado: (2022)

Anti‑BCMA CAR‑T cell immunotherapy for relapsed or refractory multiple myeloma
por: Zhang, Xiaohui, et al.
Publicado: (2023)

Donor eligibility criteria and liver graft acceptance criteria during normothermic regional perfusion: A systematic review
por: Schurink, Ivo J., et al.
Publicado: (2022)

PB1993: MULTIPLE MYELOMA BRAZILIAN REGISTER- HOW ABOUT THE TRANSPLANT ELIGIBLE PATIENTS?
por: Crusoe, E., et al.
Publicado: (2022)

An OMOP CDM-Based Relational Database of Clinical Research Eligibility Criteria
por: Si, Yuqi, et al.
Publicado: (2017)

Chia, a large annotated corpus of clinical trial eligibility criteria
por: Kury, Fabrício, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tpgsfleg8up4fi8q2dc3lk0dr4